The Oman Market
Oman's Pharmaceuticals & Life Sciences market is growing as part of Oman Vision 2040's economic diversification mandate. The Personal Data Protection Law (Royal Decree 6/2022), ITA cybersecurity guidelines, and CBO banking regulations create compliance obligations for technology deployments that are being actively enforced as the regulatory infrastructure matures.
Engineering teams deploying into Oman need current knowledge of the PDPL (2022), ITA regulatory framework, and sector-specific requirements that are evolving rapidly. Organizations that deploy generic Gulf compliance documentation into Oman discover the gaps when the ITA or sector regulator reviews the system architecture. We deploy with Oman-specific regulatory mapping from day one.
Compliance Coverage
Every system we deploy for Pharmaceuticals & Life Sciences in Oman is FDA 21 CFR Part 11-compliant from architecture through deployment. FDA 21 CFR Part 11 and HIPAA compliance is enforced automatically at every commit — not assessed after the fact.
Engagement Scope
Duration: 8–16 weeks
A focused team deployed against a single Pharmaceuticals & Life Sciences platform in Oman. FDA 21 CFR Part 11 and HIPAA-compliant architecture from day one. Fixed price, fixed output, no discovery phase.
Duration: 3–9 months
40–100 engineers running parallel workstreams across a Pharmaceuticals & Life Sciences transformation in Oman. Multi-system compliance governance and FDA 21 CFR Part 11 and HIPAA certification maintained across the full program.
Duration: 6–18 months
100–250+ engineers owning the complete technology infrastructure for a Pharmaceuticals & Life Sciences organization in Oman. Full FDA 21 CFR Part 11 and HIPAA compliance across every system, every integration, every deployment.